Liver stereotactic ablative radiotherapy: an effective and feasible alternative to surgery during the COVID-19 pandemic
Affiliation
The Royal Marsden NHS Foundation Trust, London, UK.Issue Date
2020
Metadata
Show full item recordAbstract
The COVID-19 pandemic is having an unprecedented impact on UK cancer services. Access to radical surgery has been severely restricted and resources for systemic therapy provision are being limited as the crisis unfolds. Radiotherapy resources are rightly being focused on patients being treated with curative intent. However, it is our experience that access to stereotactic ablative radiotherapy (SABR) is diminishing, predominantly due to staffing shortages. SABR offers a non-invasive, outpatient ablative approach with minimal hospital footfall and with lower immunosuppressive risks than chemotherapy. The recently published long-term outcomes of the SABR COMET study illustrate the ability of SABR to substantially impact survival across tumour types [1]. The NHS England Commissioning through Evaluation process has shown that SABR can be safely delivered in the UK [2,3]. SABR requires specialist multidisciplinary expertise. The majority of radiotherapy departments are planning to maintain their capacity for category 1?4 treatments [4] and many have therefore suspended SABR for oligometastatic disease. However, we are concerned that diminishing access to SABR, at a time when access to other curative local treatment modalities is already restricted, will result in poorer patient outcomes in the short and medium term when this need not be the case. Patients with liver-limited colorectal cancer have a 5-year survival of 40% following surgery [5]. Given the evidence supporting SABR for colorectal liver metastases [6], we believe that this should be prioritised if patients are unable to access surgery and interventional ablative techniques. Similarly, SABR should be considered for patients with hepatocellular carcinoma while access to other services (particularly transplant) is limited. We urge radiotherapy departments to preserve access to SABR for patients in these situations, particularly as the COVID-19 pandemic wanes and staffing levels allow the re-establishment of normal services.Citation
K. Aitken, J. Good, M. Hawkins et al. Liver Stereotactic Ablative Radiotherapy: an Effective and Feasible Alternative to Surgery during the COVID-19 Pandemic. Clin Oncol (R Coll Radiol). 2020Journal
Clinical OncologyDOI
10.1016/j.clon.2020.04.012PubMed ID
32387045Additional Links
https://dx.doi.org/10.1016/j.clon.2020.04.012Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2020.04.012
Scopus Count
Collections
Related articles
- Radiotherapy and Systemic Treatment for Non-melanoma Skin Cancer in the COVID-19 Pandemic.
- Authors: Rembielak A, Sykes AJ, Fife K, Challapalli A, Nobes JP
- Issue date: 2020 Jul
- COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern Italy.
- Authors: Jereczek-Fossa BA, Palazzi MF, Soatti CP, Cazzaniga LF, Ivaldi GB, Pepa M, Amadori M, Antognoni P, Arcangeli S, Buffoli A, Beltramo G, Berlinghieri S, Bignardi M, Bracelli S, Bruschieri L, Castiglioni S, Catalano G, Di Muzio N, Fallai C, Fariselli L, Filippi AR, Gramaglia A, Italia C, Lombardi F, Magrini SM, Nava S, Orlandi E, Pasinetti N, Sbicego EL, Scandolaro L, Scorsetti M, Stiglich F, Tonoli S, Tortini R, Valdagni R, Vavassori V, Marvaso G, CODRAL (Board of Directors of Radiation Oncology Departments in Lombardy) network
- Issue date: 2020 Jul
- Lymphocytopenia and Radiotherapy Treatment Volumes in the Time of COVID-19.
- Authors: Joseph N, Choudhury A
- Issue date: 2020 Jul
- A recommendation for IVF lab practice in light of the current COVID-19 pandemic.
- Authors: Arav A
- Issue date: 2020 Jul
- The Virtual Scientific Sessions from the American Society of Breast Surgeons During the COVID-19 Pandemic.
- Authors: Kuerer HM, Blair SL
- Issue date: 2020 Nov